Classic anesthetic strategy

Phase 3Small molecule

UUniversity Hospital, Bordeaux

Classic anesthetic strategy is one of 19 small molecule programs targeting Anesthesia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnesthesiaNot yet recruiting

AnesthesiaPhase 3

Not yet recruiting

Competition

Competitive Landscape

30 competitors in Anesthesia

#DrugCompanyPhaseTrials

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

10 2

Versed

CConrado Roberto Hoffmann Filho

Approved

4 3

Sufenta

LLeaf Vertical Inc.

Approved

4 4

Iheezo

BB. Braun Medical Inc.

Approved

3 5

Xylocaine

MMEDRx USA, Inc.

Phase 1

12 6

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

7 7

Classic anesthetic strategy

UUniversity Hospital, Bordeaux

Phase 3

1 8

Duragesic

CCephalon

Preclinical

6 9

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

2 10

Ultram

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Not yet recruiting

Anesthesia

NCT07149077

Clinical

Trials by Indication[1]

Anesthesia1 trial

Echo-guided Scalp Blocks and Incidence of Postoperative Pain in Scheduled Supratentorial Intracranial Surgery.

Not yet recruiting·UUniversity Hospital, Bordeaux·Phase 3·NCT07149077·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Classic anesthetic strategy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Classic anesthetic strategy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Classic anesthetic strategy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bordeaux company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Bordeaux

Classic anesthetic strategy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Anesthesia1 trial

References

Drug Info

Quick Facts

Related News